FDA approves Rocket's gene therapy for ultra-rare immune disease

Lei Lei Wu / endpoints - A rare disease gene therapy from Rocket Pharmaceuticals has garnered FDA approval after an earlier rejection for manufacturing problems. The FDA on Thursday granted accelerated approval to Rocket Pharma’s gene therapy ...

AI Summary: The FDA granted approval to Rocket’s gene therapy for a pediatric immune disorder, marking the first regulatory ok for this specific treatment class in children and offering a one‑time corrective option for affected patients. The decision opens access while raising expectations for long‑term follow‑up and real‑world safety monitoring.

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda #infanthealth #clinicaltrials

Making custom CRISPR therapies could be harder than initially thought

3 months / endpoints / Ryan Cross

FDA Approval Makes Rocket Pharma Gene Therapy the First for Ultra-Rare Immune Disorder

3 months / medcitynews / Frank Vinluan

FDA approves gene therapy for severe leukocyte adhesion deficiency-I, a rare immune disorder

3 months / medicalxpress

FDA approves 1st gene therapy for pediatric immune disorder

3 months / beckershospitalreview / Ella Jeffries

FDA approves Rocket's gene therapy for ultra-rare immune disease

3 months / endpoints / Lei Lei Wu

FDA approves Rocket's gene therapy for ultra-rare immune disease

Related Stories